<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Giugliano, Robert</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Beneficial Effects of Once-Daily Edoxaban in Patients with AF</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-13</style></pages><abstract><style  face="normal" font="default" size="100%">This article reports the results of the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation—TIMI 48 trial [ENGAGE AF-TIMI 48]. This randomized, double-blind, double-dummy trial of 21,105 patients demonstrated the efficacy and safety of a once-daily regimen of the oral anticoagulant edoxaban in treatment of atrial fibrillation (AF). The primary trial results have been published [Giugliano RP et al. N Engl J Med 2013].</style></abstract><number><style face="normal" font="default" size="100%">24</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>